Combining Prostate‐Specific Antigen Density With PI‐RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion‐Targeted Re‐Biopsy
The Prostate · 2025
DOI: 10.1002/pros.70117 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Yuto Ono und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostate-Specific Antigen, Magnetic Resonance Imaging, Prostate. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
The diagnostic reliability of magnetic resonance imaging (MRI)/transrectal ultrasound (TRUS) fusion‐targeted re‐biopsy for prostate cancer (PCa) remains limited. Therefore, additional predictive markers are needed to improve patient selection. This study aimed to identify factors predictive of clinically significant PCa (csPCa) to develop a risk stratification model. The role of systematic biopsies was also investigated.
Methods
We retrospectively analyzed 194 patients who underwent MRI/TRUS fusion‐targeted re‐biopsies between 2017 and 2024. Lesions were scored according to the Prostate Imaging Reporting and Data System (PI‐RADS) version 2.0 or 2.1. Univariate and multivariate logistic regression analyses were conducted to identify predictors of csPCa, defined as Gleason score ≥ 3 + 4. Detection rates for csPCa were compared between groups. The diagnostic contribution of systematic biopsies was assessed separately.
Results
Of the 194 patients, 82 (42.3%) were diagnosed with csPCa. Multivariate analysis identified prostate‐specific antigen density (PSAD) ≥ 0.20 (odds ratio (OR): 6.56) and PI‐RADS ≥ 4 (OR: 12.38) as independent predictors of csPCa. Based on the PI‐RADS category and PSAD, patients were stratified into high‐, intermediate‐, and low‐risk groups. These risk stratification factors led to the classification of 83 (42.8%) patients as high‐risk, 77 (39.7%) as intermediate‐risk, and 34 (17.5%) as low‐risk, with csPCa detection rates of 74.7% (62/83), 24.7% (19/77), and 2.9% (1/34), respectively. Of the 82 patients with csPCa, 21 were diagnosed exclusively via systematic biopsies.
Conclusions
Combining PSAD with PI‐RADS improved risk stratification for csPCa in men who underwent MRI/TRUS fusion re‐biopsies, while systematic biopsies added diagnostic value. These findings support individualized evidence‐based re‐biopsy strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.
- Department of Urology, JA Hiroshima General Hospital, Hiroshima, Japan.
- Department of Diagnostic Radiology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.
- Kasumi Clinic, Hiroshima, Japan.
- Department of Pathology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.
ORCID-Profile: Yuto Ono, Shunsuke Miyamoto, Kohei Kobatake, Yohei Sekino, Hiroyuki Kitano, Nobuyuki Hinata
Zitieren
APA
Ono, Y., Kohada, Y., Tasaka, S., Miyamoto, S., Hayashi, T., Honda, Y., Kitamura, N., Tasaka, R., Kobatake, K., Sekino, Y., Kitano, H., Goto, K., Goriki, A., Hieda, K., Kato, M., Takeshima, Y., & Hinata, N. (2025). Combining Prostate‐Specific Antigen Density With PI‐RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion‐Targeted Re‐Biopsy. The Prostate. https://doi.org/10.1002/pros.70117
Vancouver
Ono Y, Kohada Y, Tasaka S, Miyamoto S, Hayashi T, Honda Y, et al. Combining Prostate‐Specific Antigen Density With PI‐RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion‐Targeted Re‐Biopsy. The Prostate. 2025. doi:10.1002/pros.70117
BibTeX
@article{Ono2025,
author = {Ono, Yuto and Kohada, Yuki and Tasaka, Shinsaku and Miyamoto, Shunsuke and Hayashi, Tetsutaro and Honda, Yukiko and Kitamura, Naoyuki and Tasaka, Ryo and Kobatake, Kohei and Sekino, Yohei and Kitano, Hiroyuki and Goto, Keisuke and Goriki, Akihiro and Hieda, Keisuke and Kato, Masao and Takeshima, Yukio and Hinata, Nobuyuki},
title = {Combining Prostate‐Specific Antigen Density With PI‐RADS to Improve the Detection of Clinically Significant Prostate Cancer at MRI/TRUS Fusion‐Targeted Re‐Biopsy},
journal = {The Prostate},
year = {2025},
doi = {10.1002/pros.70117}
}
EUVIMED